Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled study of pelacarsen in patients with established cardiovascular disease and elevated lipoprotein(a)
CTR20200647Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pelacarsen in cardiac morbidity, lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Novartis. Started Sep 2020; status: completed.
02
Drugs
pelacarsen
03
Conditions
cardiac morbiditylipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20200647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200647.